Skip to search formSkip to main contentSkip to account menu

BMS 540215

Known as: BMS-540215, BMS540215, VEGFR2 Inhibitor BMS-540215 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

brivanib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Therapeutic efficacy of a synthetic epsin mimetic peptide in glioma tumor model: uncovering multiple mechanisms beyond the VEGF-associated tumor angiogenesis
Binding of epsin ubiquitin-interacting motif (UIM) with ubiquitylated VEGFR2 is a critical mechanism for epsin-dependent VEGFR2… 
2017
2017
Ascorbate lacks significant influence in rats with bile duct ligation‐induced liver injury
2016
2016
Mass balance, pharmacokinetics, and metabolism of [14C] brivanib (BMS-582664), prodrug of BMS-540215, in subjects with advanced or metastatic solid tumors.
3566 Background: Brivanib alaninate (BMS-582664, B) is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR… 
2014
2014
Quality by design development of brivanib alaninate tablets: degradant and moisture control strategy.
2011
2011
Metabolism and Disposition of [ 14 C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans □ S
: Brivanib [( R )-1-(4-(4-fluoro-2-methyl-1 H -indol-5-yloxy)-5-methyl-pyrrolo[1,2,4]triazin-6-yloxy)propan-2-ol, BMS-540215] is… 
2009
2009
Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate
PurposeBrivanib alaninate is a prodrug of brivanib (BMS-540215), a potent oral VEGFR-2 inhibitor and is currently in development… 
2008
2008
A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced…
4111 Background: Brivanib alaninate (B) is an oral prodrug of BMS-540215, a dual tyrosine kinase inhibitor of VEGFR and FGFR… 
2007
2007
Translational Use of Imaging in Early Drug Development
ED03-03 Novel imaging technologies offer unprecedented opportunities to image tumor biology. Rather than merely documenting site… 
2006
2006
Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
3051 Background: This is the first multiple-dose study with BMS-582664, an oral VEGFR/FGFR tyrosine kinase inhibitor (IC50 34, 10… 
2005
2005
Preclinical studies of BMS-582664, an alanine prodrug of BMS-540215, a potent, dual inhibitor of VEGFR-2 and FGFR-1 kinases
Proc Amer Assoc Cancer Res, Volume 46, 2005 3033 The growth, survival and dissemination of tumors is critically dependent on… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)